TOKYO, March 10, 2026 /PRNewswire/ — TIER IV, the pioneering force behind open-source software for autonomous driving, has officially joined the Automotive Chiplet Program (ACP) overseen by imec, a world-leading research and innovation center in nanoelectronics and digital technologies. This partnership serves as a technical foundation for TIER IV’s multi-environment, multi-application strategy, designed to deliver scalable autonomous driving solutions across the global mobility ecosystem.

A unified strategy for the SDV era

As the industry pivots toward software-defined vehicles (SDVs), the decoupling of hardware and software has become a competitive necessity. TIER IV is addressing this through two key pillars:

• Multi-environment: Ensures compatibility with vehicles from automakers, Autoware*, open-source software for autonomous driving, and hardware architectures, including system-on-chips and sensors.
• Multi-application: Supports various use cases through system development and integration, embedded vehicles, reference designs, and customary services.

Chiplet technology is an approach to building semiconductors by combining various chips with specific functions. By participating in the ACP, TIER IV is advocating for chiplet-based architectures that allow these diverse software applications to run efficiently across different silicon platforms. This modularity ensures that vehicle manufacturers can utilize the best-in-class processing for their specific needs without being locked into a single proprietary hardware vendor.

From LiDAR processing to AI acceleration

A critical component of this collaboration is the co-design of specialized hardware accelerators. TIER IV has already achieved a major milestone by finalizing the development of a LiDAR accelerator, designed for high-speed 3D point-cloud processing.

Building on this success, TIER IV is now focusing its research within the ACP on AI accelerators tailored for AI-based autonomous driving. As Autoware moves toward neural networks that handle everything from perception to planning, the hardware must evolve to support high-throughput AI workloads. Chiplet technology allows TIER IV to integrate its perception expertise directly into the system-on-chip alongside other compute tiles, ensuring the low latency and high efficiency required for future auto-grade autonomous systems.

“Our strategy is built on the principle that autonomous driving should be adaptable to any platform and any use case,” said Shinpei Kato, founder and CEO of TIER IV. “Joining imec’s ACP allows us to harmonize open-source software with silicon based on open standards. Regardless of the underlying computing architecture, our goal is to ensure that Autoware and our AI-based models deliver peak performance through optimized chiplet designs.”

“We’re delighted to welcome TIER IV to imec’s ACP,” said Bart Placke, VP imec Automotive. “As the automotive industry transitions toward chiplet architectures, it is increasingly clear that this shift cannot happen in isolation. That’s why ACP brings the ecosystem together in a pre-competitive effort to align on standards and validate approaches that meet automotive-grade requirements. With TIER IV on board for this program, we can combine our semiconductor and system integration expertise with their leading capabilities in autonomous driving software and reference platforms. Together, we aim to accelerate the maturation of chiplet-based architectures that will underpin the next generation of safe, reliable, scalable and energy-efficient autonomous mobility.”

Building the future of open hardware

TIER IV is working with a global ecosystem of industry leaders to define the pre-competitive standards for automotive chiplets through the ACP. This collaborative effort ensures that the Autoware Foundation’s Open AD Kit and TIER IV’s Co-MLOps platform remain at the cutting edge of semiconductor innovation. By championing an open, interoperable chiplet ecosystem, TIER IV is fostering a transparent supply chain that accelerates the path to safe and scalable autonomous driving worldwide.

*Autoware is a registered trademark of the Autoware Foundation.

About TIER IV

TIER IV stands at the forefront of deep tech innovation, pioneering Autoware, open-source software for autonomous driving. With a comprehensive suite of platforms and services built around Autoware, TIER IV provides everything from software development and vehicle procurement to operational support. Through the Autoware ecosystem, TIER IV works with partners worldwide to shape the future of intelligent vehicles with open-source software, aiming to create mobility that is safer, more sustainable, and accessible to all.

Media contact
pr@tier4.jp

Built alongside auditors and industry experts, the new solution sets a new benchmark for financial transparency, compliance, and operational scale for short-term rental property managers across Australia and New Zealand.

SYDNEY, March 10, 2026 /PRNewswire/ — Guesty, the global property management software leader for the short-term rental industry, today announced the launch of its fully compliant trust accounting solution for property managers across Australia and New Zealand (ANZ). Built to align with the region’s most demanding regulatory framework, Queensland trust accounting regulations, the new infrastructure sets a new benchmark for financial compliance and operational confidence in the short-term rental industry.

Guesty Launches Fully Compliant Trust Accounting Aligned with Australia’s Highest Regulatory Standards

Trust accounting in Australia is among the most rigorous financial frameworks property managers operate within. For short-term rental operators managing growing portfolios, maintaining compliance while scaling operations has long been a complex and resource-intensive challenge.

Guesty’s new trust accounting solution was developed to address that challenge head-on.

Built in collaboration with one of Australia’s leading trust accounting auditing firms and backed by nearly 30 years of local trust accounting expertise, the solution combines deep regulatory knowledge with Guesty’s global product development capabilities to deliver the most advanced trust accounting infrastructure available to short-term rental property managers in the region.

Unlike traditional accounting systems that operate separately from operational platforms, Guesty’s trust accounting is built directly into its industry-leading property management software, allowing property managers to manage financial operations, owner reporting, and portfolio performance within a single system.

• Full compliance aligned with Queensland’s rigorous trust accounting regulatory standards
• Transparent financial visibility across properties, owners, and portfolios
• Automated workflows designed to reduce manual reconciliation and reporting complexity
• Integrated accounting infrastructure built directly into Guesty’s best-in-class PMS
• Local expert support from an Australian-based trust accounting team

Together, these capabilities allow property managers across Australia and New Zealand to manage financial operations with confidence while continuing to scale their businesses.

“This launch represents a major milestone for the short-term rental industry in Australia and New Zealand,” said Yoav Tourel, Managing Director, APAC at Guesty. “Trust accounting has traditionally been one of the most complex and stressful parts of operating a property management business in the region. By working alongside auditors and industry experts, we’ve built a solution that meets the highest regulatory standards while making financial operations significantly easier for operators.”

With the introduction of fully compliant trust accounting aligned to Australia’s most demanding regulatory framework, Guesty continues to expand the infrastructure supporting professional property managers as the short-term rental industry grows and matures globally.

About Guesty

Guesty, the end-to-end platform built for the short-term rental industry, empowering property managers and hosts to grow smarter, scale faster, and deliver standout guest experiences. With the largest R&D team in the industry, Guesty is the engine inside more than 500,000 properties across 100+ countries, powering more properties, more platforms, and more bookings across major OTAs like Airbnb, Vrbo, Booking.com, Expedia, Tripadvisor, Hopper, Google Travel, and Homes & Villas by Marriott. Backed by $410 million in funding from KKR, Apax Digital Fund, Inovia Capital, DFO Management (formerly MSD Capital), Sixth Street Growth, Viola Growth, and Flashpoint, Guesty’s global team is building the future of the short-term rental industry under one roof, for every platform, every property, and every tool.

Guesty’s platform is designed to deliver: maximum occupancy, maximum revenue, maximum ease, and the highest guest and owner satisfaction. Learn more at guesty.com.

Contact details

Michelle Chiera
Head of Communications & PR
Michelle.Chiera@guesty.com

• Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html

MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed.

Key findings include:

• Tolerability profile supported by dosimetry and low-grade non-hematologic events.
• Lesion dosimetry indicates no difference in absorbed dose profile across cohorts.
• No adverse drug-drug interactions observed in TLX591-Tx combinations.
• Hematologic events are in line with expectations and transient and manageable, with similar rates of recovery across all patient cohorts.
• The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.

Part 1 of the study confirmed the safety profile, biodistribution and dosimetry of TLX591-Tx administered in two doses, 14 days apart, in combination with one of three standard of care (SOC) therapies: abiraterone, enzalutamide or docetaxel. The patient population comprised prostate-specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) patients previously treated with one androgen receptor pathway inhibitor (ARPI).

ProstACT Global is a differentiated Phase 3 trial comparing PSMA-targeted ¹⁷⁷Lu-rADC therapy administered with SOC versus SOC alone, a trial design intended to reflect current global clinical practice^[1]. Telix has already advanced the study into Part 2 – a 2:1 randomized treatment expansion – in jurisdictions where the clinical trial has obtained approval from health authorities^[2]. Part 1 data will be presented to the United States (U.S.) Food and Drug Administration (FDA) to seek an Investigational New Drug (IND) amendment to progress Part 2 in the U.S.

Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, Salt Lake City, and ProstACT Global Principal Investigator and Steering Committee member, commented, “These results reinforce the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC, including ARPIs such as enzalutamide or abiraterone, or docetaxel. Hematologic events align with those typically seen in this patient population and therapeutic class, and these cases resolved quickly. The dosimetry profile, along with the low-grade nature of non-hematologic adverse events, further supports the tolerability profile of this investigational therapy.”

David N. Cade, MD, Group Chief Medical Officer, Telix added, “Despite advances in clinical practice, men with advanced prostate cancer still need improved first and second line treatment options. These results build on prior findings and highlight the potential for TLX591-Tx in combination with contemporary standard of care, to become a new first-line option for patients facing this aggressive disease. We are encouraged by the data and look forward to engaging with the FDA at the earliest opportunity, while continuing to advance enrollment in Part 2 in regions where clinical trial initiation has already been approved.”

Summary results

ProstACT Global Part 1 dosed 36 patients, allocated across 3 cohorts:

• Cohort 1 (11 patients): TLX591-Tx + enzalutamide.
• Cohort 2 (11 patients): TLX591-Tx + abiraterone.
• Cohort 3 (14 patients): TLX591-Tx followed by docetaxel.

Safety and tolerability

• An acceptable safety profile was observed across combination cohorts and tolerability of TLX591-Tx was consistent with prior studies.  
• All 36 patients received both doses of TLX591-Tx per protocol, no new safety signals were observed.
• Almost all treatment-emergent non-hematologic events were Grade 1 or Grade 2. The most prevalent were fatigue (53%), nausea (28%) and dry mouth (25%).
• Hematologic events were transient and manageable.
• Grade 3 thrombocytopenia (14%) and neutropenia (22%), and Grade 4 thrombocytopenia (31%) and neutropenia (25%) events were in line with the profile expected for this class of therapy and extent of disease.

Dosimetry and biodistribution

• Radiation exposure to key organs was well below established safety limits^[3].
• Limited dose to salivary glands and kidneys.
• Lesion dosimetry demonstrated uptake across tumor sites and across all cohorts.
• Pharmacokinetics demonstrated sustained activity at 15 days, corroborated by imaging which demonstrated prolonged tumor retention.
• No evidence of drug-drug interactions impacting TLX591-Tx targeting, distribution or clearance.

About ProstACT Global

ProstACT Global (ClinicalTrials.gov ID: NCT06520345) is an international, multicenter trial in two parts: Part 1, safety and dosimetry lead-in with 36 patients (complete); and Part 2, 2:1 randomized global expansion with an overall target enrollment of approximately 490 patients. Eligible patients must have confirmed progressive mCRPC assessed with a ⁶⁸Ga-PSMA-11 PET^[4] imaging agent (such as Illuccix®, kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection, or Gozellix®, kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) following prior treatment with one ARPI.

The antibody approach demonstrates different targeting and pharmacology to that observed in other PSMA-targeted small molecule radioligand therapies (RLT). In contrast to these therapies^[5], collective long-term follow-up of patients administered with TLX591-Tx has not observed significant acute or delayed kidney toxicity, as the agent is primarily cleared through the liver, a comparatively radioresistant organ, instead of the kidneys^[6]. Due to its large molecular weight, TLX591-Tx also demonstrates minimal salivary and lacrimal gland uptake, reducing dry mouth and dry eyes, common adverse effects of existing PSMA-targeted RLTs^[7].

Additional information on the Phase 3 ProstACT Global study can be found at: https://telixpharma.com/prostact/

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, with the goal to address significant unmet medical needs in oncology and rare diseases. With international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan, Telix is headquartered in Melbourne, Australia. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Telix’s Precision Medicine franchise includes llluccix®, approved in multiple markets globally, and Gozellix®, approved by the U.S. FDA^[8]. TLX591-Tx has not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. 

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

^[1] National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for Prostate Cancer V3.2026; Narayan et al. Clin Genitourin Cancer. 2024.
^[2] Part 2 is enrolling in Australia, New Zealand, and Canada, and has also received regulatory approval to commence in China, Singapore, South Korea, Türkiye, and the United Kingdom.
^[3] Wahl et al. J Nucl Med. 2021; Emami et al. Int J Radiat Oncol Biol Phys. 1991.
^[4] Positron emission tomography.
^[5] Tagawa et al. Curr Oncol Rep. 2021; Steinhelfer et al. J Nucl Med. 2024.
^[6] Tagawa et al. Cancer. 2019.
^[7] Pepin et al. Pract Radiat Oncol. 2025. 
^[8] Telix ASX disclosure March 21, 2025.

NEW YORK, March 10, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides an afternoon update directly from the NYSE Trading Floor. Access today’s NYSE afternoon update for insights before the Closing Bell.

Paris Hilton to ring NYSE Closing Bell on March 9th.

• The New York Stock Exchange will mark Monday’s Closing Bell in honor of International Women’s Day, celebrated on Sunday, March 8, 2026.
• Paris Hilton, Founder and CEO of 11:11 Media, along with activist Gloria Steinem, will ring the Closing Bell.
• Hilton will spotlight Back in Business, an initiative supporting women-owned small businesses rebuilding after the January 2025 Los Angeles Wildfires.
• Following the fires, 11:11 Media awarded 50 grants to women-owned businesses in partnership with the Pasadena Women’s Business Center and GoFundMe.

Paris Hilton, Founder & CEO of 11:11 Media, alongside activist Gloria Steinem will ring the New York Stock Exchange (NYSE) Closing Bell at 4:00 p.m. E.T. in celebration of International Women’s Day to honor the leadership, resilience, and impact of women across business, media, and culture.

Paris Hilton will also highlight Back in Business, a new initiative from 11:11 Media that spotlights women owned small businesses rebuilding in the wake of the January 2025 Los Angeles wildfires. Following the fires, 11:11 Media’s Impact team mobilized to support affected families and small businesses, awarding grants to 50 women owned businesses in partnership with the Pasadena Women’s Business Center and GoFundMe.

Back in Business continues that effort through a six-episode YouTube series, sharing the stories of these women entrepreneurs as they recover, rebuild, and grow. The program underscores the importance of sustained investment in women led businesses and long-term community recovery.

Click to watch the Closing Bell live on Taking Stock starting at 3:58 p.m. ET today

NEW YORK, March 10, 2026 /PRNewswire/ — Ridgewood Infrastructure, a leading investment firm focused on essential infrastructure in the United States, today announced that it has acquired a controlling interest in Sierra Railroad Company (“Sierra”), a California-based shortline rail platform providing freight rail, switching, storage, and transloading services to a diversified customer base across key essential industrial, agricultural, and energy supply chains. Simultaneously with Ridgewood’s investment Sierra is acquiring Central Valley Ag Transport (“CVAT“) an agricultural products transload facility owner and operator serving customers along Sierra’s rail network.

Sierra’s operating subsidiaries include Sierra Northern Railway (“Sierra Northern”), which owns and operates the freight rail business and provides switching, storage, and transloading services across approximately 130 miles of track in California. Sierra Northern’s network is strategically located near core dairy and agricultural regions, major West Coast ports, and industrial demand centers, enabling critical last-mile connectivity across essential supply chains.

Sierra Northern benefits from strategically located Class I interchanges, including access to both Union Pacific Railroad and BNSF Railway, providing customers with enhanced network redundancy, routing flexibility, and connectivity to national rail markets.

The transaction also includes Sierra’s subsidiary Railpower, Inc., which owns and operates the only Federal Railroad Administration (“FRA”)–approved hydrogen-powered locomotive in the United States, reflecting Sierra’s leadership in rail innovation and zero-emissions locomotive technology.

The acquisition of CVAT strengthens Sierra’s platform by vertically integrating agricultural transload capabilities that are essential to California’s dairy and broader agricultural industry. CVAT provides specialized transloading services along Sierra Northern’s network, enabling efficient movement of feed and agricultural products while deepening customer relationships and increasing rail utilization.

“Sierra is a high-quality shortline rail platform with strong fundamentals, a diversified customer base, and a strategic footprint in some of California’s most important industrial and agricultural corridors,” said Ryan Stewart, Partner at Ridgewood Infrastructure. “Our team brings deep experience owning and operating shortline and other railroad businesses across the United States, and we see meaningful opportunities to build on Sierra’s strong foundation by driving additional freight volumes for both existing customers and new customers, expanding transload capabilities, and supporting innovation across the platform.”

“This partnership with Ridgewood marks an important next step for Sierra,” said Kennan H. Beard III, Chief Executive Officer of Sierra Northern. “Ridgewood’s experience operating rail and infrastructure businesses, combined with their investment approach, gives us the resources and support to accelerate execution across the platform. We are focused on growing volumes, expanding transload capacity, and continuing to serve our customers with the reliability and responsiveness they expect.”

“In selecting a partner for Sierra, it was critical to find an investor with the sector expertise, aligned strategic perspective, and financial capacity to support the company’s next phase of growth,” said Mike Hart, Founder of Sierra Railroad Corporation who has led the company since its acquisition in 1995. “Sierra had reached a point where meaningful near-term investment was required to pursue identified opportunities.”

“Ridgewood stood apart as a differentiated, value-added partner with a deep understanding of the rail industry and a proven track record of building lower middle-market infrastructure businesses,” Mr. Hart added. “Their experience and approach made them the right long-term owner for Sierra, and I am pleased to remain a significant investor alongside Ridgewood.”

Ridgewood was advised by King & Spalding and Truist Securities. Sierra was advised by Northborne Partners. Debt financing for the transaction was provided by Brookfield Infrastructure Credit.

About Ridgewood Infrastructure

Ridgewood Infrastructure invests in essential infrastructure businesses across the transportation, energy, utilities, and industrial sectors. The firm focuses on assets that provide critical services, exhibit durable demand, and offer opportunities for value creation through operational improvement and strategic growth.

About Sierra Railroad Company

Sierra Railroad Company is a California-based rail platform whose subsidiaries include Sierra Northern Railway, a shortline freight rail operator providing switching, storage, and transloading services across approximately 130 miles of track; and Railpower, Inc., a hydrogen locomotive business.

About Central Valley Ag Transport

Central Valley Ag Transport is an agricultural products transload operator serving dairy farmers and agricultural customers along Sierra Northern Railroad’s network.

Contact info:  
For More Information:  
Ridgewood Infrastructure  
34 East 51st Street, 9th Floor  
New York, NY 10022  
Phone: (212) 867-0050  
Inquiries@RidgewoodInfrastructure.com

Logo – https://laotiantimes.com/wp-content/uploads/2026/03/ridgewood_logo.jpg 

NEW YORK, March 10, 2026 /PRNewswire/ — MCO (MyComplianceOffice), a leading provider of compliance management software for financial services firms, has been named to Chartis Research’s Financial Crime and Compliance50 (FCC50) for the second consecutive year, rising to number 17.

MCO Rises to Number 17 on Chartis Research’s Financial Crime and Compliance50 2026

The Financial Crime Compliance50 report evaluates top vendors in financial crime technology, focusing on innovation in key areas including anti-money laundering (AML), fraud detection, sanctions screening, and Know Your Customer (KYC) compliance. The independent assessment considers market influence, technological innovation, and strategic vision, highlighting the firms shaping the future of financial crime compliance software.

MCO also won the following awards:

• Data Tech Category: Regional Due Diligence Data
• Emerging Use Cases Category: Know Your Transaction Award
• Functionality Category: Perpetual KYC Award

“MCO’s rise in the FCC50 ranking reflects several notable achievements, as well as the quality of its functionality in the areas of AML transaction monitoring, name screening, adverse media, case management and KYC,’ said Sean O’Malley, Research Director at Chartis. ‘Alongside strong revenue performance, market knowledge and industry reputation – with a presence in multiple business verticals, emerging markets and mid- and lower-tier banks – MCO is continuing to invest in R&D to enable future software enhancements.”

Daragh Tracey, MCO’s Director of Product for Financial Crime, added: “As the financial services industry continues to evolve, we’re committed to staying at the forefront of compliance technology. Inclusion on the FCC50 list reflects our dedication to reducing cost, effort, and risk for our client firms. We are delighted to receive this recognition and remain committed to providing greater value and functionality for customers with trusted AML, KYC, and transaction monitoring tools – all delivered through a single platform and single data set across the key areas of compliance.”

The MyComplianceOffice platform empowers financial services firms to proactively manage Know Your Customer, Third Party Risk Management, and Anti-Money Laundering compliance using real-time analytics, intelligent workflows, and centralized oversight. To learn more about MCO’s award-winning financial crime compliance solutions, visit mycomplianceoffice.com.

About MCO (MyComplianceOffice)
MCO provides integrated compliance management software that enables global financial services firms to operate efficiently, ethically, and compliantly. With 30+ products on a single system, the powerful MyComplianceOffice platform enables compliance professionals to demonstrate that they are proactively managing compliance obligations and the regulated activities of employees, third-party relationships and financial transactions.

1500+ client companies across 125+ countries use MyComplianceOffice to move away from manual processes and disparate systems with a superior compliance ecosystem that delivers significantly reduced cost and risk.